TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07729579: An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face

Sponsor: Sun Pharmaceutical Industries Limited · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 48 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07729579 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07729579 Rescue Dossier →